Copyright © 2012 Chun-Hsu Pan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. A. N. Baer and R. L. Wortmann, “Myotoxicity associated with lipid-lowering drugs,” Current Opinion in Rheumatology, vol. 19, no. 1, pp. 67–73, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
2. J. Adams, Z. P. Chen, B. J. W. Van Denderen et al., “Intrasteric control of AMPK via the γ1 subunit AMP allosteric regulatory site,” Protein Science, vol. 13, no. 1, pp. 155–165, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
3. J. M. Lee, W. Y. Seo, K. H. Song et al., “AMPK-dependent repression of hepatic gluconeogenesis via disruption of CREB·CRTC2 complex by orphan nuclear receptor small heterodimer partner,” Journal of Biological Chemistry, vol. 285, no. 42, pp. 32182–32191, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
4. D. G. Hardie, “The AMP-activated protein kinase pathway—new players upstream and downstream,” Journal of Cell Science, vol. 117, no. 23, pp. 5479–5487, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
5. E. O. Ojuka, “Role of calcium and AMP kinase in the regulation of mitochondrial biogenesis and GLUT4 levels in muscle,” Proceedings of the Nutrition Society, vol. 63, no. 2, pp. 275–278, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
6. D. G. Hardie and D. A. Pan, “Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase,” Biochemical Society Transactions, vol. 30, no. 6, pp. 1064–1070, 2002. View at Publisher · View at Google Scholar · View at Scopus
7. P. R. Clarke and D. G. Hardie, “Regulation of HMG-CoA reductase: identification of the site phosphorylated by the AMP-activated protein kinase in vitro and in intact rat liver,” EMBO Journal, vol. 9, no. 8, pp. 2439–2446, 1990. View at Scopus
8. Z. An, H. Wang, P. Song, M. Zhang, X. Geng, and M. H. Zou, “Nicotine-induced activation of AMP-activated protein kinase inhibits fatty acid synthase in 3T3L1 adipocytes: a role for oxidant stress,” Journal of Biological Chemistry, vol. 282, no. 37, pp. 26793–26801, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
9. Y. L. Huang, S. H. Loke, C. C. Hsu, and W. F. Chiou, “(+)-Vitisin A inhibits influenza A virus-induced RANTES production in A549 alveolar epithelial cells through interference with Akt and STAT1 phosphorylation,” Planta Medica, vol. 74, no. 2, pp. 156–162, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
10. K. T. Ku, Y. L. Huang, Y. J. Huang, and W. F. Chiou, “Miyabenol A inhibits LPS-induced NO production via IKK/IκB inactivation in RAW 264.7 macrophages: possible involvement of the p38 and PI3K pathways,” Journal of Agricultural and Food Chemistry, vol. 56, no. 19, pp. 8911–8918, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
11. Y. L. Huang, W. J. Tsai, C. C. Shen, and C. C. Chen, “Resveratrol derivatives from the roots of Vitis thunbergii,” Journal of Natural Products, vol. 68, no. 2, pp. 217–220, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
12. L. L. Lin, C. Y. Lien, Y. C. Cheng, and K. L. Ku, “An effective sample preparation approach for screening the anticancer compound piceatannol using HPLC coupled with UV and fluorescence detection,” Journal of Chromatography B, vol. 853, no. 1-2, pp. 175–182, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
13. S. C. Peng, C. Y. Cheng, F. Sheu, and C. H. Su, “The antimicrobial activity of heyneanol A extracted from the root of taiwanese wild grape,” Journal of Applied Microbiology, vol. 105, no. 2, pp. 485–491, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
14. I.-M. Chung, M.-A. Yeo, S.-J. Kim, and H.-I. Moon, “Neuroprotective effects of resveratrol derivatives from the roots of Vitis thunbergii var. sinuate against glutamate-induced neurotoxicity in primary cultured rat cortical cells,” Human and Experimental Toxicology, vol. 30, no. 9, pp. 1404–1408, 2011. View at Publisher · View at Google Scholar · View at PubMed
15. C. K. Wang, L. G. Chen, C. L. Wen et al., “Neuroprotective activity of vitis thunbergii var. taiwaniana extracts in vitro and in vivo,” Journal of Medicinal Food, vol. 13, no. 1, pp. 170–178, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
16. W. F. Chiou, C. C. Shen, C. C. Chen, C. H. Lin, and Y. L. Huang, “Oligostilbenes from the roots of Vitis thunbergii,” Planta Medica, vol. 75, no. 8, pp. 856–859, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
17. S. C. Yang, Studies on the Chemical Constituents of the Stems of Vitis thunbergii Sieb. et Zucc, M.S. thesis, China Medical University, Taichung, Taiwan, 2005.
18. J. M. Wu, Z. R. Wang, T. C. Hsieh, J. L. Bruder, J. G. Zou, and Y. Z. Huang, “Mechanism of cardioprotection by resveratrol, a phenolic antioxidant present in red wine (Review),” International journal of molecular medicine, vol. 8, no. 1, pp. 3–17, 2001. View at Scopus
19. H. Berrougui, G. Grenier, S. Loued, G. Drouin, and A. Khalil, “A new insight into resveratrol as an atheroprotective compound: inhibition of lipid peroxidation and enhancement of cholesterol efflux,” Atherosclerosis, vol. 207, no. 2, pp. 420–427, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
20. V. R. Ramprasath and P. J. H. Jones, “Anti-atherogenic effects of resveratrol,” European Journal of Clinical Nutrition, vol. 64, no. 7, pp. 660–668, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
21. S. Das, G. A. Cordis, N. Maulik, and D. K. Das, “Pharmacological preconditioning with resveratrol: Role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation,” American Journal of Physiology, vol. 288, no. 1, pp. H328–H335, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
22. S. Das and D. K. Das, “Resveratrol: a therapeutic promise for cardiovascular diseases,” Recent Patents on Cardiovascular Drug Discovery, vol. 2, no. 2, pp. 133–138, 2007. View at Publisher · View at Google Scholar · View at Scopus
23. R. I. Kirk, J. A. Deitch, J. M. Wu, and K. M. Lerea, “Resveratrol decreases early signaling events in washed platelets but has little effect on platelet aggregation in whole blood,” Blood Cells, Molecules, and Diseases, vol. 26, no. 2, pp. 144–150, 2000. View at Publisher · View at Google Scholar · View at Scopus
24. U. R. Pendurthi, J. T. Williams, and L. V. M. Rao, “Resveratrol, a polyphenolic compound found in wine, inhibits tissue factor expression in vascular cells: a possible mechanism for the cardiovascular benefits associated with moderate consumption of wine,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 2, pp. 419–426, 1999. View at Scopus
25. R. Zini, C. Morin, A. Bertelli, A. A. E. Bertelli, and J. P. Tillement, “Effects of resveratrol on the rat brain respiratory chain,” Drugs under Experimental and Clinical Research, vol. 25, no. 2-3, pp. 87–97, 1999. View at Scopus
26. M. Jang and J. M. Pezzuto, “Cancer chemopreventive activity of resveratrol,” Drugs under Experimental and Clinical Research, vol. 25, no. 2-3, pp. 65–77, 1999. View at Scopus
27. P. S. Ray, G. Maulik, G. A. Cordis, A. A. E. Bertelli, A. Bertelli, and D. K. Das, “The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury,” Free Radical Biology and Medicine, vol. 27, no. 1-2, pp. 160–169, 1999. View at Publisher · View at Google Scholar · View at Scopus
28. S. K. Manna, A. Mukhopadhyay, and B. B. Aggarwal, “Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-κB, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation,” Journal of Immunology, vol. 164, no. 12, pp. 6509–6519, 2000. View at Scopus
29. Y. Kimura, H. Okuda, and M. Kubo, “Effects of stilbenes isolated from medicinal plants on arachidonate metabolism and degranulation in human polymorphonuclear leukocytes,” Journal of Ethnopharmacology, vol. 45, no. 2, pp. 131–139, 1995. View at Publisher · View at Google Scholar · View at Scopus
30. S. Das and D. K. Das, “Anti-inflammatory responses of resveratrol,” Inflammation and Allergy—Drug Targets, vol. 6, no. 3, pp. 168–173, 2007. View at Publisher · View at Google Scholar · View at Scopus
31. E. Ignatowicz and W. Baer-Dubowska, “Resveratrol, a natural chemopreventive agent against degenerative diseases,” Polish Journal of Pharmacology, vol. 53, no. 6, pp. 557–569, 2001. View at Scopus
32. S. V. Penumathsa, M. Thirunavukkarasu, S. Koneru et al., “Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat,” Journal of Molecular and Cellular Cardiology, vol. 42, no. 3, pp. 508–516, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
33. K. K. R. Rocha, G. A. Souza, G. X. Ebaid, F. R. F. Seiva, A. C. Cataneo, and E. L. B. Novelli, “Resveratrol toxicity: effects on risk factors for atherosclerosis and hepatic oxidative stress in standard and high-fat diets,” Food and Chemical Toxicology, vol. 47, no. 6, pp. 1362–1367, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
34. D. Miura, Y. Miura, and K. Yagasaki, “Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearing rats,” Life Sciences, vol. 73, no. 11, pp. 1393–1400, 2003. View at Publisher · View at Google Scholar · View at Scopus
35. L. Rivera, R. Morón, A. Zarzuelo, and M. Galisteo, “Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats,” Biochemical Pharmacology, vol. 77, no. 6, pp. 1053–1063, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
36. J. Ahn, I. Cho, S. Kim, D. Kwon, and T. Ha, “Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet,” Journal of Hepatology, vol. 49, no. 6, pp. 1019–1028, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
37. I. J. Cho, J. Y. Ahn, S. Kim, M. S. Choi, and T. Y. Ha, “Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters,” Biochemical and Biophysical Research Communications, vol. 367, no. 1, pp. 190–194, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
38. G. M. Do, E. Y. Kwon, H. J. Kim et al., “Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice,” Biochemical and Biophysical Research Communications, vol. 374, no. 1, pp. 55–59, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
39. G. V. Gnoni and G. Paglialonga, “Resveratrol inhibits fatty acid and triacylglycerol synthesis in rat hepatocytes,” European Journal of Clinical Investigation, vol. 39, no. 3, pp. 211–218, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
40. D. M. Goldberg, S. E. Hahn, and J. G. Parkes, “Beyond alcohol: beverage consumption and cardiovascular mortality,” Clinica Chimica Acta, vol. 237, no. 1-2, pp. 155–187, 1995. View at Publisher · View at Google Scholar · View at Scopus
41. P. J. Barter, M. Caulfield, M. Eriksson et al., “Effects of torcetrapib in patients at high risk for coronary events,” New England Journal of Medicine, vol. 357, no. 21, pp. 2109–2122, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
42. M. Gomaraschi, D. Baldassarre, M. Amato et al., “Normal vascular function despite low levels of high-density lipoprotein cholesterol in carriers of the apolipoprotein A-IMilano mutant,” Circulation, vol. 116, no. 19, pp. 2165–2172, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
43. B. L. Trigatti, M. Krieger, and A. Rigotti, “Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 10, pp. 1732–1738, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
44. T. B. César, M. R. M. Oliveira, C. H. Mesquita, and R. C. Maranhão, “High cholesterol intake modifies chylomicron metabolism in normolipidemic young men,” Journal of Nutrition, vol. 136, no. 4, pp. 971–976, 2006. View at Scopus
45. R. Clarke, C. Frost, R. Collins, P. Appleby, and R. Peto, “Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies,” British Medical Journal, vol. 314, no. 7074, pp. 112–117, 1997. View at Scopus
46. M. You and C. Q. Rogers, “Adiponectin: a key adipokine in alcoholic fatty liver,” Experimental Biology and Medicine, vol. 234, no. 8, pp. 850–859, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
47. T. Kusakabe, H. Tanioka, K. Ebihara et al., “Beneficial effects of leptin on glycaemic and lipid control in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and a high-fat diet,” Diabetologia, vol. 52, no. 4, pp. 675–683, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
48. C. L. Lin, H. C. Huang, and J. K. Lin, “Theaflavins attenuate hepatic lipid accumulation through activating AMPK in human HepG2 cells,” Journal of Lipid Research, vol. 48, no. 11, pp. 2334–2343, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
49. J.-F. Liu, Y. Ma, Y. Wang, Z.-Y. Du, J.-K. Shen, and H.-L. Peng, “Reduction of lipid accumulation in HepG2 Cells by luteolin is associated with activation of AMPK and Mitigation of oxidative stress,” Phytotherapy Research, vol. 25, no. 4, pp. 588–596, 2011. View at Publisher · View at Google Scholar · View at PubMed
50. M. Zang, A. Zuccollo, X. Hou et al., “AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells,” Journal of Biological Chemistry, vol. 279, no. 46, pp. 47898–47905, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
51. G. Zhou, R. Myers, Y. Li et al., “Role of AMP-activated protein kinase in mechanism of metformin action,” Journal of Clinical Investigation, vol. 108, no. 8, pp. 1167–1174, 2001. View at Publisher · View at Google Scholar · View at Scopus
52. J. Shang, L. L. Chen, and F. X. Xiao, “Resveratrol improves high-fat induced nonalcoholic fatty liver in rats,” Zhonghua Gan Zang Bing Za Zhi, vol. 16, no. 8, pp. 616–619, 2008. View at Scopus
53. J. M. Ajmo, X. Liang, C. Q. Rogers, B. Pennock, and M. You, “Resveratrol alleviates alcoholic fatty liver in mice,” American Journal of Physiology, vol. 295, no. 4, pp. G833–G842, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
54. J. Shang, L. L. Chen, F. X. Xiao, H. Sun, H. C. Ding, and H. Xiao, “Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase,” Acta Pharmacologica Sinica, vol. 29, no. 6, pp. 698–706, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
55. J. L. Goldstein and M. S. Brown, “Atherosclerosis: the low-density lipoprotein receptor hypothesis,” Metabolism, vol. 26, no. 11, pp. 1257–1275, 1977. View at Scopus
56. M. S. Brown and J. L. Goldstein, “Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth,” Journal of Lipid Research, vol. 21, no. 5, pp. 505–517, 1980. View at Scopus
57. H. Rudney and R. C. Sexton, “Regulation of cholesterol biosynthesis,” Annual Review of Nutrition, vol. 6, pp. 245–272, 1986. View at Scopus